Synthetic Biologics, Inc.(NYSE Amex Equities : SYN)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | 0.87% | 204.66 | 1.3% | $437.29m | |
| BIIB | Biogen Inc. | 0.13% | 226.06 | 1.3% | $385.70m | |
| GILD | Gilead Sciences, Inc. | 1.23% | 65.30 | 0.9% | $366.87m | |
| CELG | Celgene Corporation | 0.56% | 100.95 | 1.3% | $350.36m | |
| ILMN | Illumina, Inc. | 0.60% | 312.17 | 3.5% | $264.87m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.53% | 303.82 | 2.6% | $218.75m | |
| EXAS | Exact Sciences Corporation | 5.16% | 99.74 | 24.1% | $209.91m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 3.42% | 104.81 | 2.0% | $187.13m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 1.47% | 176.14 | 1.9% | $179.12m | |
| A | Agilent Technologies, Inc. | 0.76% | 75.75 | 1.6% | $150.80m | |
| SRPT | Sarepta Therapeutics, Inc. | 2.74% | 88.05 | 14.6% | $142.65m | |
| ALDR | Alder Biopharmaceuticals, Inc. | -0.21% | 18.88 | 10.2% | $128.87m | |
| BMRN | BioMarin Pharmaceutical Inc. | 1.89% | 68.51 | 4.3% | $96.67m | |
| ACAD | ACADIA Pharmaceuticals Inc. | 1.72% | 40.16 | 13.4% | $89.24m | |
| SGEN | Seattle Genetics, Inc. | 1.17% | 83.38 | 6.2% | $85.21m |
Company Profile
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.